Natera, Inc. ($NTRA) Stock Forecast: Up 5.8% Today

What is Natera, Inc.?

Natera, Inc. (NTRA) is a genetic testing company specializing in molecular testing for women's health, oncology, and organ health. Today, NTRA experienced a strong bullish movement in the stock market.

Why is Natera, Inc. going up?

NTRA stock is up 5.8% on Mar 4, 2026 15:23

• The Chief Legal Officer of Natera receiving a significant number of restricted stock units (RSUs) aligns his incentives with the company's performance, indicating confidence in the company's future prospects.
• Mentioned company's reiteration of a Buy rating and positive revenue forecast for 2026 boosted investor confidence, leading to an increase in Natera's stock price.
• Despite a price target cut for Natera by a specific investment firm, other analysts maintaining Buy ratings and positive outlooks on the company's earnings and revenue growth contributed to the bullish market movement.
• The overall positive sentiment towards Natera, driven by strong Q4 results and optimistic forecasts, outweighed concerns over recent market volatility and inflation, leading to the stock's upward trajectory.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Natera (NTRA) awards 12,272 RSUs to chief legal officer Rabinowitz

Natera, Inc. (NTRA) has granted 12,272 restricted stock units (RSUs) to its Chief Legal Officer, Daniel Rabinowitz, as reported in a recent Form 4 SEC filing. These RSUs will vest over four years, with 25% vesting on March 1, 2027, and the remainder in 12 equal quarterly installments. Following this award, Daniel Rabinowitz directly owns 236,085 shares of Natera common stock, aligning his long-term incentives with the company's equity performance.

https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-96a88b4e4110.html

Natera (NTRA) Stock Trades Up, Here Is Why

Natera (NTRA) stock increased by 4.3% after Canaccord Genuity reiterated its Buy rating following strong Q4 2025 results that exceeded forecasts. The genetic testing company also provided an optimistic revenue forecast for 2026, boosting investor confidence despite recent market volatility and concerns over persistent inflation impacting the broader market.

https://finviz.com/news/328776/natera-ntra-stock-trades-up-here-is-why

Strive Asset Management LLC Invests $1.61 Million in Natera, Inc. $NTRA

Strive Asset Management LLC initiated a new position in Natera, Inc. (NASDAQ:NTRA) during the third quarter, purchasing 10,000 shares valued at approximately $1.61 million. This investment comes as Natera exceeded quarterly earnings forecasts, reporting $0.35 EPS against an estimated ($0.46) and revenue of $665.5 million against $600.7 million. Despite significant insider selling over the past 90 days, analysts maintain a "Moderate Buy" rating with an average target price of $254.47 for the medical research company.

https://www.marketbeat.com/instant-alerts/filing-strive-asset-management-llc-invests-161-million-in-natera-inc-ntra-2026-03-03/

Morgan Stanley Cuts Price Target on Natera to $250 From $265, Keeps Overweight Rating

Morgan Stanley has lowered its price target for Natera to $250 from $265, while maintaining an "Overweight" rating on the stock. This adjustment follows other recent analyst activity, including UBS raising its price target on Natera to $290 from $280, also keeping a "Buy" rating. Natera, a diagnostics company specializing in molecular testing for women's health, oncology, and organ health, recently reported its Q4 2025 earnings with revenue rising and operating loss narrowing.

https://www.marketscreener.com/news/morgan-stanley-cuts-price-target-on-natera-to-250-from-265-keeps-overweight-rating-ce7e5cd2d98ff22d

Rafferty Asset Management LLC Has $7.63 Million Stock Holdings in Natera, Inc. $NTRA

Rafferty Asset Management LLC reduced its stake in Natera, Inc. by 17.8% during the third quarter, now holding 47,408 shares valued at approximately $7.63 million. Despite beating quarterly earnings expectations with $0.35 EPS against an estimated -$0.46, Natera remains unprofitable, reporting a negative net margin and return on equity. Insiders have sold a significant amount of stock recently, though the company generally receives a "Moderate Buy" consensus rating from analysts with an average price target of $254.47.

https://www.marketbeat.com/instant-alerts/filing-rafferty-asset-management-llc-has-763-million-stock-holdings-in-natera-inc-ntra-2026-03-03/

Trending Today

Silver ($XAG) Commodity Forecast: Up 5.0% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.4% Today

Ethereum ($ETH) Crypto Forecast: Up 5.9% Today

Natural Gas ($GAS) Commodity Forecast: Down 9.0% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 16.6% Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 19.9% Today

Gasoline ($GASOLINE) Commodity Forecast: Down 13.5% Today

Crude Oil ($CRUDE) Commodity Forecast: Down 19.2% Today

ZCash ($ZEC) Crypto Forecast: Up 5.4% Today

American Airlines Group Inc. ($AAL) Stock Forecast: Up 6.2% Today

Natera, Inc. Price History

04.01.2026 - NTRA Stock was down 8.9%

• The decrease in Natera Inc. (NTRA) stock value may be due to a combination of strong revenue performance but a miss in earnings per share, as well as recent insider selling.
• Concerns around regulatory approval timelines and market potential arose following the FDA premarket approval application for Natera's Signatera CDx test in muscle-invasive bladder cancer (MIBC).
• Despite analyst optimism with a "Moderate Buy" rating and a high target price, the surge in institutional ownership and insider selling likely led to short-term selling pressure, contributing to the bearish market trend.

04.01.2026 - NTRA Stock was down 7.7%

• The decline in Natera's stock today may be influenced by various factors:
• Positive developments, such as the FDA PMA application for the Signatera CDx test for bladder cancer, were overshadowed by concerns related to the company's financial performance. Natera fell short on EPS, and significant insider selling took place, amounting to over $114 million in the previous quarter.
• The substantial insider selling likely created selling pressure on the stock in the short term.
• Despite increased stakes by institutional investors like the New York State Common Retirement Fund and Mirae Asset Global Investments Co. Ltd., the notable insider selling and earnings miss could have affected overall investor sentiment.
• While the decrease in short interest in January suggested a decline in bearish sentiment, today's market movement implies that other factors impacted the stock more significantly.

08.00.2026 - NTRA Stock was down 5.4%

• Despite recently reaching an all-time high, Natera Inc. (NTRA) experienced a bearish market movement today, possibly due to concerns raised about the stock's valuation compared to its Fair Value.
• The company's financial outlook, supported by positive developments such as the expanded Fetal Focus test and ALTAIR trial results, still harbors uncertainties regarding further reimbursement and guideline wins to counterbalance high expenses.
• The bearish movement may also be influenced by projections of negative net income for the year, despite increased price targets from various firms.
• Investors may be exercising caution regarding the stock's valuation and the company's capacity to convert clinical progress into sustainable financial growth, contributing to the observed bearish market movement today.

06.00.2026 - NTRA Stock was up 6.3%

• The positive outcomes presented at the ASCO GI Symposium from its ALTAIR trial, showcasing significant disease-free survival benefits for colorectal cancer patients, likely contributed to Natera's bullish movement.
• Natera's stock price target was increased to $270 by Guggenheim, along with other analysts' optimistic adjustments, fueling investor confidence.
• The launch of the expanded 21-gene Fetal Focus single-gene non-invasive prenatal test further demonstrates Natera's commitment to innovation and product expansion, attracting more attention from investors.
• Strong revenue growth and positive market sentiment have driven the stock price upwards, overshadowing concerns such as insider selling and reduced stake by Calamos Advisors LLC.

12.00.2026 - NTRA Stock was down 5.5%

• The bearish movement in Natera's stock price today could be attributed to several factors:
• Despite Natera's strong preliminary fourth-quarter revenue and positive news surrounding its oncology tests, the market may have reacted negatively to President Moshkevich's significant stock sale, which could have raised concerns among investors.
• The collaboration with Exelixis on the STELLAR-316 trial for colorectal cancer patients, while promising in the long term, might have created uncertainty in the short term due to the expected initiation of the trial in mid-2026.
• The lack of specific details in the findings from the CALGB (Alliance)/SWOG 80702 study could have left investors wanting more clarity on the potential impact of the study results on Natera's products and services.
• Overall market conditions or sector-specific trends may have also played a role in the bearish movement of Natera's stock today, despite the positive developments highlighted in recent news.

22.00.2026 - NTRA Stock was up 5.1%

• Acquisition of a new position in Natera by Rakuten Investment Management Inc. reflects confidence in the company's future.
• Study results for Natera's colorectal cancer detection assay have been promising, showcasing the company's innovative technology and growth potential.
• Natera's publication of clinical validation for its tfMRD test in colorectal cancer reinforces its position as a leader in precision oncology.
• Selection of Natera's Fetal Focus sgNIPT for a prestigious presentation at the SMFM meeting underlines the company's advancements in genetic screening, likely contributing to positive market sentiment.

04.02.2026 - NTRA Stock was up 5.8%

• The Chief Legal Officer of Natera receiving a significant number of restricted stock units (RSUs) aligns his incentives with the company's performance, indicating confidence in the company's future prospects.
• Mentioned company's reiteration of a Buy rating and positive revenue forecast for 2026 boosted investor confidence, leading to an increase in Natera's stock price.
• Despite a price target cut for Natera by a specific investment firm, other analysts maintaining Buy ratings and positive outlooks on the company's earnings and revenue growth contributed to the bullish market movement.
• The overall positive sentiment towards Natera, driven by strong Q4 results and optimistic forecasts, outweighed concerns over recent market volatility and inflation, leading to the stock's upward trajectory.

06.01.2026 - NTRA Stock was down 6.2%

• Natera's President and Chief Business Officer selling a substantial amount of company stock to cover tax obligations might have signaled a lack of confidence in the company's short-term performance, contributing to the bearish movement.
• The sale of Natera stock by the President of Clinical Diagnostics, following a period of stock volatility and concerns about overvaluation, could have added to the negative sentiment among investors.
• The mid-day trading price drop of 7.82% on February 4th could be a result of a combination of insider selling, perceived overvaluation, and overall market volatility affecting Natera's stock price.
• The AI-driven trading systems highlighting weak near-term sentiment despite long-term strength might have influenced traders to react to the short-term risks associated with Natera, leading to the bearish movement in the stock price.

05.01.2026 - NTRA Stock was down 5.5%

• The bearish market movement of NTRA stock could be linked to insider selling activities by the company's top executives, such as President Moshkevich and President Fesko, leading to concerns among investors about the company's future prospects.
• Despite strong preliminary Q4 2025 results and advancements in diagnostic technologies, the stock saw a notable decline possibly because of profit-taking by insiders and investor reactions to perceived stock overvaluation.
• The submission of Signatera CDx PMA to the FDA for detecting molecular residual disease in bladder cancer patients could act as a positive long-term catalyst for Natera. However, short-term market sentiment appears influenced more by insider selling and valuation concerns.
• AI-driven trading systems highlighting weak near-term sentiment and a significant risk-reward setup targeting an 11.5% gain might have also contributed to increased volatility and downward pressure on NTRA stock.

11.11.2025 - NTRA Stock was down 3.8%

• Insider selling, specifically by company directors and the CEO, could be a reason behind Natera's stock downturn, despite recent positive developments like the acquisition of Foresight Diagnostics and strong Q3 results.
• The acquisition of Foresight Diagnostics for up to $450 million may have raised investor concerns about integration challenges and potential value dilution.
• While institutional investors have significantly increased their positions and analysts have given positive ratings, ongoing insider selling, especially by top management, has created uncertainty and possibly triggered stock sell-offs.
• Despite optimistic analyst outlooks and robust revenue performance, continuous insider selling activities, including by key executives, might have unsettled investors and contributed to the bearish trend in Natera's stock today.

18.01.2026 - NTRA Stock was up 5.5%

• Anticipation and positive sentiment among investors were fueled by Natera's announcement of the upcoming release of its fourth quarter and full-year results.
• Institutional investors, such as Zweig DiMenna Associates LLC, increased their stake, indicating confidence in Natera's future performance and contributing to the bullish trend.
• Despite some company insiders selling off shares, the market remains optimistic about Natera's growth potential, evident from the stock's positive movement.
• An average price target of $249.20 alongside analysts' "Moderate Buy" consensus rating bode well for Natera, reinforcing the bullish market sentiment.

27.01.2026 - NTRA Stock was down 6.6%

• Notable insider selling of Natera shares could be influencing the bearish trend, possibly indicating reservations or a lack of confidence among company insiders.
• Despite promising results from Phase 2 trials related to head and neck cancer, the market response may have been negative due to concerns surrounding the upcoming earnings announcement, with analysts predicting a per-share loss.
• The expectation of an unfavorable EPS in the forthcoming earnings report may have outshone the positive trial outcomes, contributing to a pessimistic outlook among investors.
• The divergence between the favorable trial results and the projected earnings loss could be causing uncertainty and fluctuations in Natera's stock value, resulting in the observed bearish sentiment in the market.